Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ESRRG | P62508 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.42 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444557 | 0.88 | NPC1 (0.50) | P2RX1NAMPTPTGER3 | |
| SCHEMBL6447053 | 0.86 | CSNK2A2 (0.49) | TP53MAPTPTGER3 | |
| SCHEMBL6445844 | 0.85 | ABL1 (0.48) | MAPTPTGER3 | |
| SCHEMBL6444705 | 0.84 | MAPK1 (0.57) | BLMMAPK14TP53MAPT | |
| SCHEMBL6445760 | 0.84 | CSNK2A2 (0.52) | TP53MAPTPTGER3 | |
| SCHEMBL6447202 | 0.84 | KMT2A (0.46) | BLMMAPK14MAPTPTGER3 | |
| SCHEMBL6445643 | 0.83 | CSNK2A2 (0.46) | TP53MAPTPTGER3 | |
| SCHEMBL6448936 | 0.83 | KMT2A (0.51) | GRM4TP53MAPTPTGER3NR1H4 | |
| SCHEMBL6445978 | 0.83 | SNCA (0.47) | MAPK14PTGER3 | |
| SCHEMBL6446020 | 0.82 | KMT2A (0.48) | MAPTPTGER3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | claimed |
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | BRISTOL-MYERS SQUIBB COMPANY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143384-A1 | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 | SERPINE1, SERPINC1, SERPINB1 | BLM 3997/4885P2RX1 2969/4885NAMPT 318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.